Printer Friendly

Unlimited coverage for anti-rejection drugs moving toward passage.

The House Ways and Means Subcommittee unanimously approved legislation on October 5 that provides for unlimited coverage of immunosuppressive drugs for transplant patients. The action came a week after the House Commerce Committee approved a similar bill. The bill also included adding coverage for glaucoma screenings and speeding up the phase-in of lower copayments for hospital outpatient services.

Republicans defeated an effort by committee Democrats to add their $40 billion proposal prescription drugs to Medicare. Republicans insisted the plan is too big, and that the drug issue should be fought out in another venue.

The Senate Finance Committee was scheduled to discuss its version after this issue of Transplant News went to press.
COPYRIGHT 2000 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Oct 6, 2000
Words:113
Previous Article:HHS splits OPTN, SRTR contracts; bold move may end impasse with UNOS, transplant community over reg.
Next Article:UNOS upgrades data resources available to transplant recipients.


Related Articles
Two proteins may help transplants.
Combating corneal transplant rejection.
Irradiation of donor intestines prior to transplantation reduces rejection.
Woman acquires lung cancer from kidney transplant.
Chiron study suggests inhaled cyclosporine significantly increases transplant patient survival.
Experimental immunosuppressant shows promise of preventing organ rejection with fewer side effects.
Cell transplants make gains versus diabetes.
Mel Gibson (news in brief, June 2005, p.30).
Cleveland Clinic IRB gives ok to Dr. Siemionow to do face transplant.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters